Pathogenesis of diabetic nephropathy

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 853-866

  Gruden, Gabriella ^a   Viberti, GianCarlo ^b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970952039     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (195)

1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-219.
2. Quinn M, Angelico MC, Warram JH, et al. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996;39:940-945.
3. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin dependent dia betics. BMJ 1987;295:515-517.
4. Nelson RG. Prediabetic blood pressure predicts urinary albumin excretion after the onset of type 2 diabetes mellitus in Pima Indians. Diabetologia 1993;36:998-1001.
5. Krolewski AS. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. . Engl J Med 1988;318:140-145.
6. The Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 1999;16:918-925.
7. Marre M. Genetics and the prediction of complications in type 1 diabetes. Diabetes Care 1999;22[Suppl 2]:B53-B58.
8. Heesom AE, Hibberd ML, Millward A, et al. Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997;46:287-291.
9. Moczulski DK, Scott L, Antonellis A, et al. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in type 1 diabetes mellitus. Diabet Med 2000;17:111-118.
10. Mangili R, Bending JJ, Scott G, et al. Increased sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy. . Engl J Med 1998;318:146-150.
11. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus . Engl J Med 1998;318:140-145.
12. Trevisan R, Li LK, Messent J, et al. Na+/H+ antiport activity and cell growth in cultured skin fibroblasts of IDDM patients with nephropathy. Diabetes 1992;1:1239-1246.
13. Ng LL, Davies JE, Siczkowski M, et al. Abnormal sodium-lithium antiporter phenotype and turnover of immortalised lymphoblasts from type 1 diabetic patients with nephropathy. . Clin Invest 1994;93:2750-2757.
14. Koren W, Koldanov R, Pronin VS, et al. Enhanced erythrocyte Na+/H+ exchange predicts diabetic nephropathy in patients with IDDM. Diabetologia 1998;41:201-205.
15. Trevisan R, Fioretto P, Barbosa J, et al. Insulin-dependent diabetic sibling pairs are concordant for Na+/H+ antiport activity Kidney Int 1999;55:2383-2389.
16. Viberti GC. Why do we have to invoke genetic susceptibility for diabetic nephropathy. Kidney Int 1999;55:2526-2527.
17. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 1999;48:909-913
18. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1995;25:710-713.
19. Fava S, Azzopardi J, Hattersley AT, et al. Increased prevalence of proteinuria in diabetic sibs of proteinuric type 2 diabetic subjects. Am J Kidney Dis 2000;35:708-712.
20. Imperatore G, Hanson RL, Pettitt DJ. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998;47:821-830.
21. Vardarli I, Baier LJ, Hanson RL. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002;62:2176-2183.
22. Bowden DW, Sale M, Howard TD. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997;46:882-886.
23. Herman WH, Prior DE, Yassine MD, et al. Nephropathy in NIDDM is associated with cellular markers for hypertension. Diabetes Care 1993; 16:815-818.
24. Fogarty DG, Rich SS, Hanna L, et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 2000;57:250-257.
25. Mauer SM, Steffes MW, Ellis EN, et al. Structural functional relationships in diabetic nephropathy. . Clin Invest 1984;74:1143-1155.
26. Fioretto P, Steffes MW, Sutherland DEF, et al. Sequential renal biopsies in IDDM patients: structural factors associated with clinical progression. Kidney Int 1995;48:1929-1935.
27. Schleicher ED. Biochemical aspects of diabetic nephropathy. In: Mogensen CE, ed. The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic Publishers, 1997:223-233.
28. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury. Kidney Int 1999;56:1627-1637.
29. Mathiesen ER, Ronn B, Jensen T, et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990;9:245-249.
30. Krolewski AS, Lori L, Krolewski M, et al. Glycosylated haemoglobin and the risk of microalbuminuria in patients with insulin dependent diabetes mellitus. . Engl J Med 1995;332:1251-1255.
31. Lee CS, Mauer SM, Brown DM, et al. Renal transplantation in diabetes mellitus in the rat. . Exp Med 1974;139:793-800.
32. Maeur SM, Steffes MW, Sutherland DER, et al. Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 1975;24:280-285.
33. Rasch R. Prevention of diabetic glomerulopathy in streptozotocin diabetic rats. Albumin excretion. Diabetologia 1980; 18:413-416.
34. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
36. Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. . Engl J Med 1998;339:69-75.
37. Raj D, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a nephrologist's prospective. Am J Kidney Dis 2000;35:365-380.
38. Makino H, Shikata K, Hironaka K, et al. Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy. Kidney Int 1995;48:517-526.
39. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994;91:11704-11708.
40. Soulis-Liparota T, Cooper ME, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 1991;40: 1328-1334.
41. Lee HB, Cha MK, Song KI, et al. Pathogenic role of advanced glycation end products in diabetic nephropathy. Kidney Int 1997;52[Suppl 60]:S60-S65.
42. Soulis T, Thallas V, Youssef S, et al. Advanced glycation end products and the receptor for advanced glycation end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997;40:619-628.
43. Doi T, Vlassara H, Kirstein M, et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992;89:2873-2877.
44. Pugliese G, Pricci F, Romeo G, et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881-1887.
45. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. . Clin Invest 2001;108: 261-268.
46. Oldfield MD, Bach LA, Forbes JM, et al Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). . Clin Invest 2001;108:1853-1863.
47. Cogan DG. Aldose reductase and complications of diabetes. Ann Intern Med 1984;101:82-91.
48. Kador PF, Robinson WG Jr, Kinoshita JH. The pharmacology of aldose reductase inhibitors. Annu Rev Pharmacol Toxicol 1985;25:691-714.
49. Pugliese G, Tilton RG, Speedy A, et al. Modulation of haemodynamics and vascular filtration changes in diabetic rats by dietary myo-inositol. Diabetes 1990;39:312-322.
50. Olgemoller B, Schleicher E, Schwaabe S, et al. Up-regulation of myo-inositol transport compensates for competitive inhibition by glucose. Diabetes 1993;42:1119-1125.
51. Goldfarb S, Ziyadeh FN, Kern EF, et al. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular haemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991;40:465-471.
52. Hamada Y, Araki N, Horiuchi S, et al. Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant 1996; 11:95-98.
53. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
54. McCaleb ML, McKean ML, Hohman TC, et al. Intervention with aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin diabetic rats. Diabetologia 1991;34:659-701.
55. Weigert C, Brodbeck K, Lehmann R, et al. Overexpression of glutamine: fructose-6-phosphate-amidotransferase induces transforming growth factorbeta1 synthesis in NIH-3T3 fibroblasts. FEBS Lett 2001;488:95-99.
56. Burt DJ, Gruden G, Thomas SM, et al. P38 mitogen-activated protein kinase mediates hexosamine-induced TGF D1 mRNA expression in human mesangial cells. Diabetologia 2003;46:531-537.
57. Kolm-Litty V, Sauer U, Nerlich A. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. . Clin Invest 1998;101:160-169.
58. Nerlich AG, Sauer U, Kolm-Litty V, et al. Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 1998;47:170-178.
59. James LR, Ingram A, Ly H, et al. Angiotensin II activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol 2001;281(1):F151-F162.
60. Ayo SH, Radnik RA, Glass IIWF, et al. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 1990;260:F185-F191.
61. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
62. Heilig CW, Conception LA, Riser BL, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. . Clin Invest 1995;96:1802-1814.
63. Heilig CW, Liu Y, England R, et al. D-glucose stimulates mesangial cell GLUT-1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells. Implication for diabetic nephropathy. Diabetes 1997;46:1030-1039.
64. Heilig CW, Kreisberg JI, Freytag S, et al. Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression. Am J Physiol Renal Physiol 2001;280:F657-F666.
65. Mogensen CE, Christiansen CK. Blood pressure changes and renal function changes in incipient and overt diabetic nephropathy. Hypertension 1985;7: II-64-II-73.
66. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary pressure. . Clin Invest 1986;77:1925-1930.
67. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. . Engl J Med 1993;329:1456-1462.
68. Viberti GC, Moghensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;217:275-279.
69. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;11:998-1004.
70. Hostetter TH, Rennke HG, Brenner BM. The case for intra-renal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-380.
71. Zatz R, Meyer TW, Renneke HG, et al. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985;2:5963-5967.
72. Mauer SM, Steffes MW, Azar S, et al. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat. Diabetes 1978;27:738-744.
73. Thomsen OF, Andersen AR, Christiansen JS, et al. Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy; a light microscopic, morphometric study of autopsy material. Diabetologia 1984;26:361-365.
74. Bohlen L, De Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:845-92S.
75. Riser BL, Cortes P, Zhao X, et al. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. . Clin Invest 1992;90:1932-1943.
76. Harris RC, Haralson MA, Badr KF. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Lab Invest 1992;66:548-554.
77. Yasuda T, Kondo S, Homma T, et al. Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. . Clin Invest 1996;98: 1991-2000.
78. Gruden G, Zonca S, Hayward A, et al. Mechanical stretch-induced fibronectin and TGF-D1 production in human mesangial cells is P38 mitogen-activated protein kinase-dependent. Diabetes 2000;9:655-661.
79. Cortes P. Mechanical strain and high glucose-induced alterations in mesangial cell collagen metabolism: role of TGF-D1 . Am Soc Nephrol 1998;9:827-836.
80. Gnudi L, Viberti G, Raij L, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003;42: 19-24.
81. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762.
82. Benigni A, Zoja C, Remuzzi G. The renal toxicity of sustained glomerular protein traffic. Lab Invest 1995;73:461-468.
83. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. . Engl J Med 1998;12:1448-1456.
84. Border WA, Noble NA. Transforming growth factor-D'in tissue fibrosis. . Engl J Med 1994;31:1286-1292.
85. Ziyadeh FN, Han DC. Involvement of TGF-D'and its receptors in the pathogenesis of diabetic nephropathy. Kidney Int 1997;52[Suppl 60]:S7-S11.
86. Terrell TG, Working PK, Chow CP, et al. Pathology of recombinant human TGF-D1 in rats and rabbits. Int Rev Exp Pathol 1993;34B:43-67.
87. Isaka Y, Fuijiwara Y, Ueda N, et al. Glomerulosclerosis induced by in vivo transfection of TGF-D'or PDGF into rat kidney. . Clin Invest 1993;92:2597-2601.
88. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-D1 develop progressive renal disease. Lab Invest 1996;74: 991-1003.
89. Yamamoto T, Nakamura T, Noble NA, et al. Expression of TGF-D'is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993;90:1814-1818.
90. Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGF-D'1 mRNA in patients with diabetes mellitus. Kidney Int 1996;49:854-859.
91. Hill C, Flyvbjerg A, Gronbaek H, et al. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000;41:1196-1208.
92. Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-D'by anti-TGF-D'antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in streptozotocin-induced diabetic mice. Diabetes 1996;45: 522-530.
93. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97:8015-8020.
94. Ziyadeh FN, Sharma K, Ericksen M, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by activation of TGF-D. . Clin Invest 1994;93:536-542.
95. Isono M, Mogyorosi A, Han DC, et al. Stimulation of TGF-D'type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol 2000;278:F830-F838.
96. Inoki K, Haneda M, Maeda S, et al. TGF-D1 stimulates glucose uptake by enhancing GLUT-1 expression in mesangial cells. Diabetes 1999;55:1704-1712.
97. Yang C-W, Vlassara H, Peten EP. Advanced glycation end products upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994;91:9436-9440.
98. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M. Effects of high glucose and TGF-D1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002;62:901-913.
99. van Det NF, Verhagen NA, Tamsma JT. Regulation of glomerular epithelial cell production of fibronectin and transforming growth factor-beta by high glucose, not by angiotensin II. Diabetes 1997;46:834-840.
100. Wu L, Cox A, Roe C. TGF-D1 and renal injury following subtotal nephrectomy in the rats. Role of the renin angiotensin system. Kidney Int 1997;51:1553-1567.
101. Riser BL, Cortes P, Heilig C. Cyclic stretch selectively up-regulates transforming growth factor-D'isoforms in cultured rat mesangial cells. Am J Pathol 1996;148:1915-1923.
102. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces TGF-D1 and type II-TGF-D'receptor in human mesangial cells. Diabetologia 1998;41 [Suppl 1]:A38-A144.
103. Hirakata M, Kaname S, Chung U, et al. Tyrosine kinase dependent expression of TGF-D'induced by stretch in mesangial cells. Kidney Int 1997;51: 1028-1036.
104. Goldschmeding R, Aten J, Ito Y. Connective tissue growth factor CTGF: just another factor in renal fibrosis? Nephrol Dial Transplant 2000;15:296-299.
105. Murphy M, Godson C, Cannon S, et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. . Biol Chem 1999;274:5830-5834.
106. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. . Am Soc Nephrol 2000;11:25-38.
107. Wahab NA, Yevdokimova N, Weston BS. Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 2001;359 (Pt 1):77-87.
108. Twigg SM, Cao Z, McLennan SV. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143:4907-4915.
109. Frazier KS, Paredes A, Dube P, et al. Connective tissue growth factor expression in the rat remnant kidney model and association with tubular epithelial cells undergoing transdifferentiation. Vet Pathol 2000;37:328-335.
110. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999;13:1774-1786.
111. Inoki I, Shiomi T, Hashimoto G. CTGF binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002; 16: 219-222.
112. Wang S, Denichilo M, Brubaker C, et al. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 2001; 60:96-105.
113. Gore-Hyer E, Shegogue D, Markiewicz M. TGF-D1 and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002;283:F707 F716.
114. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43: 1205-1223.
115. Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. . lmmunol Methods 2002;259: 11-24.
116. Doi T, Striker LJ, Gibson CC, et al. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am J Pathol 1990;137: 541-552.
117. Giordano M, DeFronzo RA. Acute effect of human recombinant insulin-like growth factor I on renal function in humans. Nephron 1995;71:10-15.
118. Landau D, Segev Y, Afargan M, et al. Anovel somatostatin analogue prevents early renal complications in the non-obese diabetic mouse. Kidney Int 2001;60:505-512.
119. Tsukahara H, Gordienko DV, Tonshoff B, et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598-604.
120. Schreiber BD, Hughes ML, Groggel GC. Insulin-like growth factor stimulates production of mesangial cell matrix components. Clin Nephrol 1995;43:368-374.
121. Ferrara N, David-Smith T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997;18:4-25.
122. Thomas S, Vanuystel J, Gruden G, et al. VEGF receptors in human mesangium in vitro and in glomerular disease. . Am Soc Nephrol 2000;11:1236-1243.
123. lijima K, Yoshikawa N, Connoly DT, et al. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993;44:959-966.
124. Kim NH, Jung HH, Cha DR. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. . Endocrinol 2000;165: 617-624.
125. Yamagishi S, Inagaki Y, Okamoto T. Advanced glycation end productinduced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. . Biol Chem 2002;277:20309-20315.
126. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces VPF in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci U S A 1997;94:12112-12116.
127. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on VEGF production by human mesangial cells . Am Soc Nephrol 1999;10:730-737.
128. Gruden G, Araf S, Zonca S, et al. IGF-I induces VEGF in human mesangial cells via a Src-dependent mechanism. Kidney Int 2003;63:1249-1255.
129. Iglesias-de la Cruz MC, Ziyadeh FN. Effects of high glucose and TGF-D1 on the expression of collagen IV and VEGF in mouse podocytes. Kidney Int 2002;62:901-913.
130. Gruden G, Hayward A, Setti G, et al. Stretch up-regulates vascular endothelial growth factor in murine glomerular epithelial cells via a PKC-independent mechanism. Diabetologia 2002;45[Suppl 2]:1084(abst).
131. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of VEGF and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229-2239.
132. Bortoloso E, Del Prete D, Gambaro G. VEGF and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients. Ren Fail 2001;23:483-493.
133. Hovind P, Tarnow L, Oestergaard PB, et al. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57[Suppl 75]:S56-S61.
134. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against VEGF improve early renal dysfunction in experimental diabetes. . Am Soc Nephrol 2001;12: 993-1000.
135. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing VEGF antibody. Diabetes 2002;51:3090-3094.
136. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274(3 Pt 2):H1054-H1058.
137. Chen J, Braet F, Brodsky S, et al. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol 2002; 282:C1053-01063.
138. Dzau VJ, Ingelfinger JR. Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. . Hypertens 1989;7[Suppl 7] :S3-S8.
139. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunochemical and biological correlations. Am J Physiol 1993;265:F477-F486.
140. Chansel D, Czekalski S, Pham P, et al. Characterization of angiotensin II receptor subtypes in human glomeruli and mesangial cells. Am J Physiol 1992; 262:F432-F441.
141. Wolf G, Ziladeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on non-hemodynamic mechanisms. Am J Kidney Dis 197;29:153-163.
142. Kagami SK, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of TGF-D'expression in rat glomerular mesangial cells. . Clin Invest 1994;93:2431-2437.
143. Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:593-S98.
144. Ding G, Reddy K, Kapasi AA. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002;283(1):F173-F180.
145. Abbate M, Zoja C, Morigi M. TGF-D1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002;161:2179-2193.
146. Pagtalunan ME, Miller PL, Jumping-Eagle S. Podocyte loss and progressive glomerular injury in type II diabetes. . Clin Invest 1997;99:342-348.
147. Bohrer MP, Deen WM, Robertson CR, et al. Mechanism of angiotensin IIinduced proteinuria in the rat. Am J Physiol 1977;233:F13-F21.
148. Lapinski R, Perico N, Remuzzi A, et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. . Am Soc Nephrol 1996;7:653-660.
149. Doublier S, Salvidio G, Lupia E. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003;52:1023-1030.
150. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-877.
151. Hofmann MA, Schiekofer S, Isermann B. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kB. Diabetologia 1999;42:222-232.
152. Morcos M, Sayed AA, Bierhaus A. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002;51:3532-3544.
153. Pieper G, Riaz-ul-Haq J. Activation of NFκB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. Cardiovasc Pharm 1997;30:528-532.
154. Lal MA, Brismar H, Eklof AC, et al. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002;61: 2006-2014.
155. Ha H, Yu MR, Choi YJ, et al. Role of high glucose-induced nuclear factorkappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. . Am Soc Nephrol 2002;13:894-902.
156. Gruden G, Setti G, Hayward A, et al. Rosiglitazone prevents stretch-induced monocyte recruitment by inhibiting the NFkB-MCP-1 pathway in human mesangial cells. Diabetologia 2003;46[Suppl 2]:A344(abst).
157. Okado T, Terada Y, Tanaka H, et al. Smad7 mediates transforming growth factor-beta-induced apoptosis in mesangial cells. Kidney Int 2002;62:1178-1186.
158. Nagaragan RP, Chen F, Li W, et al. Repression of TGF-D1-mediated transcription by nuclear factor Κ. Biochem J 2000;348:591-596.
159. Ingram AJ, Scholey JW. Protooncogene expression and diabetic kidney injury. Kidney Int 1997;52[Suppl 60]:S70-S76.
160. Kim SI, Angel P, Lavatis R, et al. Autoinduction of TGF-D'1 is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1497.
161. Dean DC, McQuillian JJ, Weintraub S. Serum stimulation of fibronectin gene expression appears to result from rapid serum-binding of nuclear proteins to a cAMP response element. . Biol Chem 1990;265:3522-3527.
162. Shankland SJ, Scholey JW. Expression of growth related protooncogenes during renal hypertrophy. Kidney Int 1995;47:782-788.
163. Kreisberg JI, Radnik RA, Ayo SH, et al. High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 1994;46:105-112.
164. Harris RC, Akai Y, Yasuda T, et al. The role of physical forces in alterations of mesangial cell function. Kidney Int 1994;45[Suppl 45]:S17-S20.
165. Kreisberg JI, Kreisberg SH. High glucose activates PKC and stimulates fibronectin gene expression by enhancing a cAMP responsive element. Kidney Int 1995;48[Suppl 48]:S3-511.
166. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of PKC. Science 1992;258:607-614.
167. King GL, Ishii H, Koya D. Diabetic vascular dysfunction: a model of excessive activation of protein kinase C. Kidney Int 1997;52[Suppl 60]:S77-S85.
168. Messina JL, Standaert ML, Ishizuka T, et al. Role of PKC in insulin's regulation of c-fos transcription. . Biol Chem 1992;267:9223-9228.
169. Zhang J, Wang L, Petrin J, et al. Characterization of site-specific mutants altered at protein kinase C D1 isoenzyme autophosphorylation sites. Proc Natl Acad Sci U S A 1993;90:6130-6134.
170. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. . Clin Invest 1989;83:1667-1675.
171. Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by high glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-674.
172. Ayo SH, Radnik R, Garoni JA, et al. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991;261:F571-F577.
173. Xia P, Inoguchi T, Kern TS, et al. Characterisation of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-1129.
174. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
175. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci U SA 1997;94:12112-12116.
176. Weiss RH, Ramirez A. TGF-beta-and angiotensin-II-induced mesangial matrix protein secretion is mediated by protein kinase C. Nephrol Dial Transplant 1998; 13:2804-2813.
177. Homma T, Akai Y, Burns KD, et al. Activation of S6 kinase by repeated cycles of stretching and relaxation in rat glomerular mesangial cells. Evidence for involvement of protein kinase C. J Biol Chem 1992;267:23129-23135.
178. Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993;42:118-126.
179. Koya D, Jirousek MR, Lin YW, et al. Characterisation of protein kinase C beta isoform activation on the gene expression of transforming growth factorbeta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. . Clin Invest 1997;100:115-126.
180. Ishii H, Jirousek MR, Koja D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCD2 inhibitor. Science 1996;222:728-731.
181. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with PKC-D'inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439-447.
182. Osicka TM, Yu Y, Panagiotopoulos S, et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000; 49:87-93.
183. Seger R, Krebs EG. The MAPK signalling cascade. FASEB J 1995;9:726-798.
184. Haneda M, Araki S, Togawa M. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-853.
185. Dunlop ME, Muggli EE. Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress. Kidney Int 2000;57:464-475.
186. Kang MJ, Wu X, Ly H, et al. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kidney Int 1999;55:2203-2214.
187. Ingram AJ, Ly H, Thai K, et al. Activation of mesangial cell signaling cascades in response to mechanical stretch. Kidney Int 1999;55:476-485.
188. Ishida T, Haneda M, Koya D, et al. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogenactivated protein kinase. Diabetes 1999;48:595-602.
189. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogenactivated protein
190. Vasan S, Zhang X. An agent cleaving glucose-derived protein cross-linking in vitro and in vivo. Nature 1996;382:275-278.
191. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-114.
192. Border WA, Noble NA. TGF-D1 in kidney fibrosis: a target for gene therapy. Kidney Int 1997;51:1388-1396.
193. Border WA, Noble NA. Evidence that TGF-D1 should be a therapeutic target in diabetic nephropathy. Kidney Int 1998;54:1390-1391.
194. Way KJ, Chou E, King GL. Identification of PKC isoform specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000;21: 181-187.
195. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by TGF-D'receptor IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-475.